ZURICH (Reuters) – A Novartis lung drug met a categorical goals in 3 late-stage studies in patients with ongoing opposed pulmonary disease (COPD), mostly famous as smokers’ cough, a Swiss drugmaker pronounced on Monday, giving a respiratory tube a boost.
The drug, QVA149, is a multiple of Novartis’ Onbrez and a other lung drug NVA237 – a new kind of two-in-one medicine that should concede Novartis to take on marketplace personality GlaxoSmithKline.
One trial, called SHINE, showed that a once daily sip QVA149 was improved than a homogeneous sip of Onbrez and NVA237 taken individually.
Another, called BRIGHT, showed patients had a significantly improved practice continuation compared to those holding a placebo, while one named ENLIGHTEN showed QVA149 was good tolerated and that the drug had a reserve and tolerability form identical to placebo.
...
0 comments
Post a Comment